Sanofi S.A. Stock , SNYNF

	2023	2024	2025	2026	2027
Revenue	45,787	48,114	50,851	52,936	55,385
Dividend	3.69	3.90	4.16	4.34	4.17
Dividend Yield (in %)	4.13 %	4.36 %	4.63 %	4.86 %	4.68 %
EPS	8.27	9.03	9.99	10.63	11.00
P/E Ratio	10.83	9.92	8.96	8.42	8.14
EBIT	12,804	13,719	15,226	16,223	16,966
EBITDA	14,694	15,898	17,595	16,318	14,244
Net Profit	10,256	11,247	12,449	13,176	13,618
Net Profit Adjusted	10,256	11,247	12,449	13,176	13,618
Pre-Tax Profit	11,553	12,850	14,751	15,999	17,760
Net Profit (Adjusted)	9,575	10,992	12,697	13,939	14,994
EPS (Non-GAAP) ex. SOE	-	-	-	-	-
EPS (GAAP)	6.40	7.34	8.42	9.18	10.03
Gross Income	32,247	34,247	36,486	38,533	40,134
Cash Flow from Investing	-1,700	-2,010	-1,908	-2,378	-2,483
Cash Flow from Operations	10,723	12,077	13,475	15,012	15,970
Cash Flow from Financing	-6,298	-5,800	-6,381	-7,353	-6,939
Cash Flow per Share	8.79	9.82	10.92	11.31	12.83
Free Cash Flow	8,165	9,242	10,566	11,992	12,730
Free Cash Flow per Share	6.75	7.81	-	-	-
Book Value per Share	61.41	65.41	70.21	70.72	78.00
Net Debt	4,279	206	-4,604	-11,309	-14,911
Research & Development Exp.	6,858	6,988	7,171	7,282	7,566
Capital Expenditure	2,095	2,157	2,205	2,572	2,615
Selling, General & Admin. Exp.	10,440	10,560	10,717	11,091	11,237
Shareholder’s Equity	76,834	81,409	87,761	90,396	97,181
Total Assets	141,282	146,141	151,712	163,564	177,127

	Previous Quarter ending 12/31/22	Current Quarter ending 03/31/23	Next Quarter ending 06/30/23	Current Year ending 12/31/23	Next Year ending 12/31/24
Earnings Estimates
No. of Analysts	12	7	7	20	19
Average Estimate	1.714 EUR	2.051 EUR	1.762 EUR	8.272 EUR	9.027 EUR
Year Ago	1.373 EUR	1.929 EUR	1.730 EUR	8.260 EUR	8.272 EUR
Publish Date	2/3/2023	4/27/2023	7/28/2023	-	-
Revenue Estimates
No. of Analysts	10	7	7	18	17
Average Estimate	11,199 EUR	10,629 EUR	10,616 EUR	45,787 EUR	48,114 EUR
Year Ago	9,994 EUR	-	10,116 EUR	-	45,787 EUR
Publish Date	2/3/2023	4/27/2023	7/28/2023	-	-

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Sanofi Dividend Calendar

Date	Name	Dividend	*yield	Currency
2022	Sanofi S.A.	3.56	3.96	EUR
2021	Sanofi S.A.	3.33	3.76	EUR
2020	Sanofi S.A.	3.20	4.07	EUR
2019	Sanofi S.A.	3.15	3.51	EUR
2018	Sanofi S.A.	3.07	4.06	EUR
2017	Sanofi S.A.	3.03	4.22	EUR
2016	Sanofi S.A.	2.96	3.85	EUR
2015	Sanofi S.A.	2.93	3.68	EUR
2015	Sanofi S.A.	2.93	3.73	EUR
2014	Sanofi S.A.	2.85	3.77	EUR
2013	Sanofi S.A.	2.80	3.63	EUR
2012	Sanofi S.A.	2.77	3.88	EUR
2011	Sanofi S.A.	2.65	4.67	EUR
2010	Sanofi S.A.	2.50	5.22	EUR
2010	Sanofi S.A.	2.40	5.02	EUR
2009	Sanofi S.A.	2.40	4.36	EUR
2009	Sanofi S.A.	2.20	4.00	EUR
2008	Sanofi S.A.	2.07	4.56	EUR
2007	Sanofi S.A.	1.75	2.78	EUR
2006	Sanofi S.A.	1.52	2.17	EUR
2005	Sanofi S.A.	1.20	1.62	EUR
2004	Sanofi S.A.	1.02	1.73	EUR
2003	Sanofi S.A.	0.84	1.41	EUR
2002	Sanofi S.A.	0.66	1.13	EUR
2001	Sanofi S.A.	0.44	0.53	EUR

*Yield of the Respective Date

Sanofi S.A. Calendar

Event	Estimate	Info	Date
Earnings Report	2.051 EUR	Q1 2023 Earnings Release	04/27/2023
Earnings Report	1.762 EUR	Q2 2023 Earnings Release	07/28/2023
Earnings Report	-	Q3 2023 Earnings Release	10/27/2023
Earnings Report	-	Q4 2023 Earnings Release	02/07/2024
Earnings Report	-	Q1 2024 Earnings Release	04/26/2024
Earnings Report	-	Q2 2024 Earnings Release	07/29/2024
Earnings Report	-	Q3 2024 Earnings Release	10/31/2024

Sanofi S.A. Past Events

Event	Actual EPS	Info	Date
Annual General Meeting	-	Annual General Meeting	03/16/2023
Earnings Report	1.710 EUR	Q4 2022 Earnings Release	02/03/2023
Shareholders' Meeting	-	-	05/03/2022

Sanofi Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Moody’s Daily Credit Risk Score

Risk

Low
Medium
High

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Sanofi Shareholder

Owner	in %
Freefloat	87.61
L'Oréal SA	9.38
Government Pension Fund - Global (The)	2.11
Plan d'Epargne Entreprise Sanofi Synthelabo	2.01
Dodge & Cox	1.98
Dodge & Cox International Stock Fund	1.41
Vanguard Total International Stock Index Fund	1.14
Sanofi	0.97
Vanguard Developed Markets Index Fund	0.66

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Sanofi Management

Name	Job
Serge Weinberg	Chairman
Arnaud Robert	Chief Digital Officer & Executive Vice President
Raj Verma	Chief Diversity, Culture & Experience Officer
Paul Hudson	Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon	Chief Financial Officer & Executive Vice President
Dietmar P. Berger	Chief Medical Officer & Global Head-Development
Natalie Bickford	Chief People Officer & Executive Vice President
Christophe Babule	Director
Wolfgang Laux	Director
Yann Tran	Director
William J. Sibold	EVP-Specialty Care & President-North America
Julie van Ongevalle	Executive VP & Head-Consumer Healthcare
Brendan OCallaghan	Executive Vice President & Head-Industrial Affairs
Olivier Antoine M. Charmeil	Executive Vice President-General Medicines
Roy Papatheodorou	General Counsel
Nestle Frank	Global Head-Immunology Therapeutic Research Area
Josep Catlla	Head-Communication
Noel M. Geoffroy	Head-North America Consumer Healthcare
Alexandra Roger	Head-Securities Law & Capital Markets
Barbara Lavernos	Independent Director
Thomas C. Südhof	Independent Director
Patrick Kron	Independent Director
Gilles Schnepp	Independent Director
Lise Kingo	Independent Director
Fabienne Lecorvaisier	Independent Director
Diane D. Souza	Independent Director
Rachel Duan	Independent Non-Executive Director
Eva Schäfer-Jansen	Investor Relations Contact
Arnaud Delépine	Investor Relations Officer
Claire Terrazas	Vice President-Corporate Legal Affairs